Source:http://linkedlifedata.com/resource/pubmed/id/12189535
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
3
|
| pubmed:dateCreated |
2002-8-21
|
| pubmed:abstractText |
We retrospectively analyzed the relationship between busulfan average steady-state plasma concentration (C(SS)) and graft rejection in 53 children receiving busulfan/cyclophosphamide (BU/CY) preparative regimens prior to hematopoietic stem cell transplantation (HSCT). Patients received a total oral busulfan dose of 11 to 28 mg/kg followed by a total cyclophosphamide dose of 120 to 335 mg/kg in preparation for allogeneic grafts (HLA-matched or HLA partially matched sibling, parent or unrelated donor). Graft rejection occurred in eight (15%) patients. Busulfan C(SS) (P = 0.0024) was the only statistically significant predictor of rejection on univariate logistic regression analysis, with the risk of rejection decreasing with an increase in busulfan C(SS). Severe (grade 3 or 4) regimen-related toxicity (RRT) occurred in four patients. Ten patients (19%) had a busulfan C(SS) higher than 900 ng/ml, one of whom had severe RRT. Higher and variable doses of cyclophosphamide may explain the lack of a relationship between busulfan C(SS) and RRT in children. It may be possible to improve the outcome of HSCT in pediatric patients receiving the BU/CY regimen through optimization of busulfan C(SS) and better definition of the contribution of activated cyclophosphamide metabolites to toxicity.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Aug
|
| pubmed:issn |
0268-3369
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
30
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
167-73
|
| pubmed:dateRevised |
2006-4-24
|
| pubmed:meshHeading |
pubmed-meshheading:12189535-Adolescent,
pubmed-meshheading:12189535-Analysis of Variance,
pubmed-meshheading:12189535-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:12189535-Busulfan,
pubmed-meshheading:12189535-Child,
pubmed-meshheading:12189535-Child, Preschool,
pubmed-meshheading:12189535-Cyclophosphamide,
pubmed-meshheading:12189535-Drug Monitoring,
pubmed-meshheading:12189535-Female,
pubmed-meshheading:12189535-Graft Rejection,
pubmed-meshheading:12189535-Hematologic Diseases,
pubmed-meshheading:12189535-Hematopoietic Stem Cell Transplantation,
pubmed-meshheading:12189535-Histocompatibility,
pubmed-meshheading:12189535-Humans,
pubmed-meshheading:12189535-Infant,
pubmed-meshheading:12189535-Male,
pubmed-meshheading:12189535-Probability,
pubmed-meshheading:12189535-Prognosis,
pubmed-meshheading:12189535-Retrospective Studies,
pubmed-meshheading:12189535-Transplantation, Homologous,
pubmed-meshheading:12189535-Treatment Outcome
|
| pubmed:year |
2002
|
| pubmed:articleTitle |
Busulfan concentration and graft rejection in pediatric patients undergoing hematopoietic stem cell transplantation.
|
| pubmed:affiliation |
Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
|
| pubmed:publicationType |
Journal Article
|